AU2001280576A1 - Tissue-specific self-inactivating gene therapy vector - Google Patents
Tissue-specific self-inactivating gene therapy vectorInfo
- Publication number
- AU2001280576A1 AU2001280576A1 AU2001280576A AU8057601A AU2001280576A1 AU 2001280576 A1 AU2001280576 A1 AU 2001280576A1 AU 2001280576 A AU2001280576 A AU 2001280576A AU 8057601 A AU8057601 A AU 8057601A AU 2001280576 A1 AU2001280576 A1 AU 2001280576A1
- Authority
- AU
- Australia
- Prior art keywords
- tissue
- gene therapy
- therapy vector
- inactivating gene
- specific self
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21924200P | 2000-07-18 | 2000-07-18 | |
| US60219242 | 2000-07-18 | ||
| PCT/US2001/022407 WO2002006451A1 (en) | 2000-07-18 | 2001-07-17 | Tissue-specific self-inactivating gene therapy vector |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001280576A1 true AU2001280576A1 (en) | 2002-01-30 |
Family
ID=22818472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001280576A Abandoned AU2001280576A1 (en) | 2000-07-18 | 2001-07-17 | Tissue-specific self-inactivating gene therapy vector |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US6716622B2 (en) |
| AU (1) | AU2001280576A1 (en) |
| WO (1) | WO2002006451A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0415963D0 (en) * | 2004-07-16 | 2004-08-18 | Cxr Biosciences Ltd | Detection of cellular stress |
| BRPI0608829A2 (en) | 2005-04-19 | 2011-03-15 | Basf Plant Science Gmbh | method for transgenic expression with enhanced specificity in a plant, use of a chimeric nucleic acid construct, chimeric ribonucleotide sequence, expression construct, expression vector, nonhuman organism or transformed cell, transformed seed, and pharmaceutical preparation |
| US20080300202A1 (en) * | 2006-05-18 | 2008-12-04 | The State of Oregon acting by and through the State Board of Higher Education on behalf of the | Subtractive transgenics |
| US9388425B2 (en) * | 2006-10-20 | 2016-07-12 | Trustees Of Boston University | Tunable genetic switch for regulating gene expression |
| US8324367B2 (en) | 2006-11-03 | 2012-12-04 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
| US9375440B2 (en) * | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
| CN102002483B (en) * | 2010-07-19 | 2013-04-17 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Hematopoietic targeted helper adenovirus and application thereof |
| JP6320382B2 (en) | 2012-08-13 | 2018-05-09 | ザ ロックフェラー ユニヴァーシティ | Melanoma treatment and diagnosis |
| EP3736022A3 (en) | 2012-10-31 | 2021-01-20 | The Rockefeller University | Treatment and diagnosis of colon cancer |
| EP2914731B1 (en) * | 2012-11-01 | 2019-09-11 | California Institute of Technology | Reversible gene expression |
| CN103981147B (en) | 2013-02-08 | 2017-11-10 | 中国科学院上海生命科学研究院 | A kind of new method for preparing hepatic parenchymal cells |
| AU2018373028A1 (en) | 2017-11-21 | 2020-04-30 | Inspirna, Inc. | Polymorphs and uses thereof |
| US12473334B2 (en) | 2018-10-17 | 2025-11-18 | Dana-Farber Cancer Institute, Inc. | SWI/SNF family chromatin remodeling complexes and uses thereof |
| WO2020160100A1 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| MX2022007164A (en) | 2019-12-13 | 2022-09-12 | Inspirna Inc | Metal salts and uses thereof. |
| CN115023226A (en) | 2020-01-29 | 2022-09-06 | 福宏治疗公司 | Compound and use thereof |
| EP4127186A1 (en) | 2020-03-24 | 2023-02-08 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing gaucher therapeutics |
| US20230138409A1 (en) | 2020-03-24 | 2023-05-04 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing factor ix therapeutics |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| WO2024040222A1 (en) | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
| WO2024091824A1 (en) | 2022-10-26 | 2024-05-02 | Ada Forsyth Institute, Inc. | Differentiation and reprogramming of chondrocyte |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5919676A (en) * | 1993-06-24 | 1999-07-06 | Advec, Inc. | Adenoviral vector system comprising Cre-loxP recombination |
| JP4216350B2 (en) * | 1994-09-19 | 2009-01-28 | 大日本住友製薬株式会社 | Recombinant DNA viral vector for animal cell infection |
| US5712114A (en) * | 1995-06-06 | 1998-01-27 | Basf Aktiengesellschaft | Compositions for expression of proteins in host cells using a preprocollagen signal sequence |
-
2001
- 2001-07-17 AU AU2001280576A patent/AU2001280576A1/en not_active Abandoned
- 2001-07-17 WO PCT/US2001/022407 patent/WO2002006451A1/en not_active Ceased
- 2001-07-17 US US09/907,186 patent/US6716622B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6716622B2 (en) | 2004-04-06 |
| WO2002006451A1 (en) | 2002-01-24 |
| US20020022018A1 (en) | 2002-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001280576A1 (en) | Tissue-specific self-inactivating gene therapy vector | |
| AU2001291656A1 (en) | Gene silencing vector | |
| AU2001265187A1 (en) | Chimeric viral vectors for gene therapy | |
| AU1152402A (en) | Highly expressible genes | |
| WO2003018621A8 (en) | Genes | |
| AU2001257532A1 (en) | Adenoviral vectors for tumor specific gene expression and uses thereof | |
| AU2001236638A1 (en) | Evi27 gene sequences and protein encoded thereby | |
| AU2001232054A1 (en) | Vector | |
| AUPQ659800A0 (en) | Genetic sequences and uses therefor | |
| AU2001242625A1 (en) | Gene sequence | |
| AU2002337892A1 (en) | Vectors for expressing multiple transgenes | |
| AU2001246703A1 (en) | Dna immunization vectors | |
| AU2001263473A1 (en) | Palmitate desaturase gene | |
| AU2001240103A1 (en) | Reproduction-specific genes | |
| AU2001264247A1 (en) | GASC1 gene | |
| AU2001288839A1 (en) | Self-rearranging dna vectors | |
| AU2001260467A1 (en) | Integrin-targeting vectors having enhanced transfection activity | |
| AUPQ749100A0 (en) | New epilespy gene | |
| AU2001247444A1 (en) | Erbeta-mediated gene expression | |
| AU2001285743A1 (en) | Adipose-related gene | |
| GB0008966D0 (en) | Vectors for gene therapy | |
| AU4672401A (en) | Vectors | |
| AU2001259169A1 (en) | Cesert genes, proteins, and modulatory compounds | |
| AU2001278042A1 (en) | Daz genes | |
| AU2002221623A1 (en) | Gene 4 |